Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Paxil CR Labeling Adds Birth Defects Warning Based On U.S., Swedish Data

Executive Summary

FDA deemed a birth defects warning for GlaxoSmithKline's Paxil CR to be warranted after data from a Swedish birth registry supported an analysis of a U.S. managed care claims database, the agency said

You may also be interested in...

Paxil CR Labeling Adds New Data On Birth Defects; GSK Plans Further Studies

GlaxoSmithKline is conducting additional epidemiologic studies to better understand preliminary data suggesting a potential link between paroxetine use and birth defects, the company said in a "Dear Doctor" letter on revised labeling for Paxil CR and Paxil

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts